Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Mi, Zhiyong ^a   Guo, Hongtao ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73949139074     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-119     Document Type: Article

References (27)

1. Osteopontin: regulation in tumor metastasis. PY Wai PC Kuo, Cancer Metastasis Rev 2008 27 103 118 10.1007/s10555-007-9104-9 18049863
2. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. A Bellahcene MP Merville V Castronovo, Cancer Res 1994 54 2823 2826 8187059
3. The regulation and role of osteopontin in malignant transformation and cancer. MK El Tanani FC Campbell V Kurisetty D Jin M McCann PS Rudland, Cytokine Growth Factor Rev 2006 17 463 474 10.1016/j.cytogfr.2006.09.010 17113338
4. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. BD Hedley DR Welch AL Allan W Al-Katib DW Dales CO Postenka G Casey IC Macdonald AF Chambers, Int J Cancer 2008 123 526 534 10.1002/ijc.23542 18470911
5. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. J Zhao L Dong B Lu G Wu D Xu J Chen K Li X Tong J Dai S Yao, et al. Gastroenterology 2008 135 956 968 10.1053/j.gastro.2008.05.025 18555021
6. RNA Aptamer Blockade of Osteopontin Inhibits Growth and Metastasis of MDA-MB231 Breast Cancer Cells. Z Mi H Guo MB Russell Y Liu BA Sullenger PC Kuo, Mol Ther 2009 17 153 161 10.1038/mt.2008.235 18985031
7. Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. SW Lee BA Sullenger, JExpMed 1996 184 315 324
8. In vitro selection of RNA aptamers to a protein target by filter immobilization. SD Jhaveri AD Ellington, CurrProtocMolBiol 2001 Chapter 24 Unit 24.3
9. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Z Mi H Guo PY Wai C Gao PC Kuo, Carcinogenesis 2006 27 1134 1145 10.1093/carcin/bgi352 16474180
10. Overcoming obstacles to metastasis-defenses against host defences: osteopontin as a chield against attack by sytotoxic host cells. DT Denhardt AF Chambers, J Cell Biochem 1994 56 48 51 10.1002/jcb.240560109 7528752
11. Transformed mammalian cells secrete specific proteins and phosphoproteins. DR Senger DF Wirth RO Hynes, Cell 1979 16 885 893 10.1016/0092-8674(79)90103-X 88265
12. The metastasis gene osteopontin: a candidate target for cancer therapy. GF Weber, BiochimBiophysActa 2001 1552 61 85
13. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. A Bellahcene V Castronovo KU Ogbureke LW Fisher NS Fedarko, NatRevCancer 2008 8 212 226
14. Cloning and characterization of the human osteopontin gene and its promoter. N Hijiya M Setoguchi K Matsuura Y Higuchi S Akizuki S Yamamoto, Biochem J 1994 303 255 262 7945249
15. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. A O'Regan JS Berman, IntJExpPathol 2000 81 373 390
16. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. PC Brooks AM Montgomery M Rosenfeld RA Reisfeld T Hu G Klier DA Cheresh, Cell 1994 79 1157 1164 10.1016/0092-8674(94) 90007-8 7528107
17. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). GF Weber S Ashkar MJ Glimcher H Cantor, Science 1996 271 509 512 10.1126/science.271.5248.509 8560266
18. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. DR Senger CA Perruzzi, BiochimBiophysActa 1996 1314 13 24
19. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. DR Senger CA Perruzzi CF Gracey A Papadopoulos DG Tenen, Cancer Res 1988 48 5770 5774 3167835
20. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. G Chakraborty S Jain GC Kundu, Cancer Res 2008 68 152 161 10.1158/0008-5472.CAN- 07-2126 18172307
21. Vascular endothelial growth factor and osteopontin in tumor biology. N Shijubo T Uede S Kon M Nagata S Abe, CritRevOncog 2000 11 135 146
22. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. D Coppola M Szabo D Boulware P Muraca M Alsarraj AF Chambers TJ Yeatman, ClinCancer Res 2004 10 184 190 10.1158/1078-0432.CCR-1405-2 (Pubitemid 38114178)
23. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. M Nordsmark JG Eriksen V Gebski J Alsner MR Horsman J Overgaard, Radiother Oncol 2007 83 389 397 10.1016/j.radonc.2007.04.021 17499868
24. Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. IA Siddiqui Y Shukla VM Adhami S Sarfaraz M Asim BB Hafeez H Mukhtar, Pharm Res 2008 25 2135 2142 10.1007/s11095-008-9553-z 18317887
25. Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin. R Del Sordo A Cavaliere A Sidoni, Am J Dermatopathol 2007 29 470 474 10.1097/DAD.0b013e318156dceb 17890917
26. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. M El-Tanani A Platt-Higgins PS Rudland FC Campbell, J Biol Chem 2004 279 20794 20806 10.1074/jbc.M311131200 14990565
27. TIS7 regulation of the beta-catenin/Tcf-4 target gene osteopontin (OPN) is histone deacetylase-dependent. I Vietor R Kurzbauer G Brosch LA Huber, J Biol Chem 2005 280 39795 39801 10.1074/jbc.M509836200 16204248